1. Home
  2. POM vs NXL Comparison

POM vs NXL Comparison

Compare POM & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo POMDOCTOR LIMITED American Depositary Shares

POM

POMDOCTOR LIMITED American Depositary Shares

HOLD

Current Price

$0.71

Market Cap

6.5M

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$4.99

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POM
NXL
Founded
2015
2010
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
7.5M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
POM
NXL
Price
$0.71
$4.99
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.9K
116.3K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.76
EPS
N/A
N/A
Revenue
N/A
$301,647.00
Revenue This Year
N/A
$15.52
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
78.78
52 Week Low
$0.06
$0.22
52 Week High
$6.43
$7.69

Technical Indicators

Market Signals
Indicator
POM
NXL
Relative Strength Index (RSI) 38.81 68.02
Support Level $0.23 $0.36
Resistance Level $1.17 $7.69
Average True Range (ATR) 0.09 0.51
MACD -0.03 0.13
Stochastic Oscillator 26.99 62.65

Price Performance

Historical Comparison
POM
NXL

About POM POMDOCTOR LIMITED American Depositary Shares

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

Share on Social Networks: